SLC35A2 and cancer: Combined with the clinical and pathological features of CRC patients (Table 2), it was found that SLC35A2 was highly expressed in 78.33% (47/60) of cancer tissue samples, and low expression in 21.67% (13/60) of CRC tissue samples (p < 0.05).